Adverse event totals15

The totals the trial posted for each group.

1 to 15 of 15

Total	Group	Affected	At risk
Total, all-cause mortality	Dose Level 0 Phase I
Total, all-cause mortality	Dose Level 0-A Phase I
Total, all-cause mortality	Dose Level 1 Phase1
Total, all-cause mortality	Group 2 (Phase II) Placebo + Radiation + Temozolomide
Total, all-cause mortality	Group 1 (Phase II) Dasatinib + Radiation + Temozolomide
Total, other adverse events	Dose Level 0 Phase I	3	3
Total, other adverse events	Dose Level 0-A Phase I	3	3
Total, other adverse events	Dose Level 1 Phase1	7	7
Total, other adverse events	Group 2 (Phase II) Placebo + Radiation + Temozolomide	133	133
Total, other adverse events	Group 1 (Phase II) Dasatinib + Radiation + Temozolomide	62	63
Total, serious adverse events	Dose Level 0 Phase I	2	3
Total, serious adverse events	Dose Level 0-A Phase I	0	3
Total, serious adverse events	Dose Level 1 Phase1	0	7
Total, serious adverse events	Group 2 (Phase II) Placebo + Radiation + Temozolomide	52	133
Total, serious adverse events	Group 1 (Phase II) Dasatinib + Radiation + Temozolomide	23	63

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00869401/event-totals